Form 4 for MRNA Moderna
Accepted 2022-03-03 00:00:00 ET · period of report 2022-03-01 · accession 0001127602-22-008030 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-03-03 | 2022-03-02 | MRNA | Andres Juan | See remarks | S - Sale+OE | $150.00 | -2,000 | 9,069 | -18% | -$300.0K |
| D | 2022-03-03 | 2022-03-02 | MRNA | Andres Juan | See remarks | M - OptEx | $14.22 | +2,000 | 11.1K | +22% | +$28.4K |
| D | 2022-03-03 | 2022-03-02 | MRNA | Andres Juan | See remarks | M - OptEx | $0.00 | -2,000 | 18.6K | -10% | $0 |
| DM | 2022-03-03 | 2022-03-01 | MRNA | Andres Juan | See remarks | A - Grant | $0.00 | +40.5K | 32.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-02 | S | D | 2,000 | $150.00 | 9,069 | D | — | — | |
| 2 | Common | Common Stock | 2022-03-02 | M | A | 2,000 | $14.22 | 11,069 | D | — | — | |
| 3 | Derivative | Stock Option (Right to Buy) | 2022-03-02 | M | D | 2,000 | $0.00 | 18,629 | D | $14.22 · — to 2028-02-28 | 2,000 Common Stock | (F4) 25% of this option vested and became exercisable on February 27, 2019 with the remainder vesting in 12 equal quarterly installments thereafter. |
| 4 | Derivative | Restricted Stock Units | 2022-03-01 | A | A | 8,019 | $0.00 | 8,019 | D | $0.00 · — to — | 8,019 Common Stock | (F3) 25% of the shares subject to this restricted stock unit award will vest on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. |
| 5 | Derivative | Stock Option (Right to Buy) | 2022-03-01 | A | A | 32,525 | $0.00 | 32,525 | D | $149.52 · 2023-03-01 to 2032-03-01 | 32,525 Common Stock | (F2) 25% of this option will vest and become exercisable on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. |